RNA-based Translation Activators for Targeted Gene Upregulation
Overview
Authors
Affiliations
Technologies capable of programmable translation activation offer strategies to develop therapeutics for diseases caused by insufficient gene expression. Here, we present "translation-activating RNAs" (taRNAs), a bifunctional RNA-based molecular technology that binds to a specific mRNA of interest and directly upregulates its translation. taRNAs are constructed from a variety of viral or mammalian RNA internal ribosome entry sites (IRESs) and upregulate translation for a suite of target mRNAs. We minimize the taRNA scaffold to 94 nucleotides, identify two translation initiation factor proteins responsible for taRNA activity, and validate the technology by amplifying SYNGAP1 expression, a haploinsufficiency disease target, in patient-derived cells. Finally, taRNAs are suitable for delivery as RNA molecules by lipid nanoparticles (LNPs) to cell lines, primary neurons, and mouse liver in vivo. taRNAs provide a general and compact nucleic acid-based technology to upregulate protein production from endogenous mRNAs, and may open up possibilities for therapeutic RNA research.
Internal cap-initiated translation for efficient protein production from circular mRNA.
Fukuchi K, Nakashima Y, Abe N, Kimura S, Hashiya F, Shichino Y Nat Biotechnol. 2025; .
PMID: 39972222 DOI: 10.1038/s41587-025-02561-8.
Mittas D, Gavrilov Z, Ucambarlic E, Gandor C, Otify D, Becirovic E Adv Exp Med Biol. 2025; 1468:95-99.
PMID: 39930179 DOI: 10.1007/978-3-031-76550-6_16.
Ahlskog N, Svrzikapa N, Abuhamdah R, Kye M, Jad Y, Feng N Mol Ther Nucleic Acids. 2025; 36(1):102406.
PMID: 39759875 PMC: 11697566. DOI: 10.1016/j.omtn.2024.102406.
Prospects for gene therapy in polycystic kidney disease.
Chakraborty A, Yu A Curr Opin Nephrol Hypertens. 2024; 34(1):121-127.
PMID: 39499052 PMC: 11606769. DOI: 10.1097/MNH.0000000000001030.
Microproteins in cancer: identification, biological functions, and clinical implications.
Hofman D, Prensner J, van Heesch S Trends Genet. 2024; 41(2):146-161.
PMID: 39379206 PMC: 11794034. DOI: 10.1016/j.tig.2024.09.002.